PCSK9i

Evolocumab Reduces First Major Cardiovascular Events in High-Risk Patients Without Known Significant Atherosclerosis

In high-risk patients with diabetes but no known significant atherosclerosis, treatment with evolocumab significantly reduced the risk of a first…

1 month ago

This website uses cookies.